Knowledge Hub

In Argentina, PCV immunization is a highly cost effective strategy

PCV7 use in Argentina resulted in an estimated cost of US$5,599 per life year gained. The purchase of the 4 doses of vaccine for the entire cohort at a cost of US$26.5 per dose would required an investment of US$73,823,806.00. This investment would significantly reduce the number of deaths brought about by cases of meningitis, bacteremia, pneumonia, otitis media and meningitis sequelae. The resultant decrease in morbidity and mortality coupled with herd immunity offered by immunization would contribute substantially to national productivity making PCV immunization a highly cost effective strategy.

Full Citation:
Giglio, N.D., Cane, A.D., Micone, P., et al. 2010. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Vaccine. 28(11).

Title of Article: Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina

Author(s): Giglio, N.D., Cane, A.D., Micone, P., et al

Publication Year: 2010

Publication Name: Vaccine

Publication Volume: 28(11)

Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/20064478/

DOI (Digital Object Identifier): 10.1016/j.vaccine.2009.12.070

Topics: Economics & Return on Investment

Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia

Countries: Argentina

WHO Regions: Americas